《支持创新药高质量发展的若干措施》印发，创新药及产业链发展有望持续向好

Investment Rating - The investment rating for the healthcare industry is "Positive" and is maintained [8]. Core Viewpoints - The issuance of "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission on June 30, 2025, aims to enhance the support for the entire chain of innovative drug development, promoting high-quality development of innovative drugs to better meet the diverse medical and pharmaceutical needs of the public [2][6]. Summary by Relevant Sections - Research and Development: There is an increased emphasis on supporting innovative drug research and development. This includes utilizing medical insurance data for R&D, encouraging commercial health insurance to expand investment in innovative drugs, and enhancing the guidance on drug directory access policies. The focus will be on major infectious diseases, prevalent chronic diseases, pediatric medications, and rare diseases to avoid homogenization in R&D [11]. - Payment Mechanism: The report supports the inclusion of innovative drugs in the basic medical insurance drug directory and commercial health insurance innovative drug directories. It emphasizes the need for a dynamic adjustment mechanism for the basic medical insurance drug directory and improving the professional capacity for negotiation and pricing of innovative drugs [11]. - Application Process: The report suggests optimizing the drug listing process, allowing companies to choose the provinces for the first listing of innovative drugs. It also encourages timely adjustments in drug supply and procurement processes in medical institutions to meet clinical needs and ensure patient access to innovative drugs [11].